Sphingomonas Nanovesicles for Brain Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective diagnostic and treatment solutions for chronic diseases such as hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, and atopic dermatitis, as existing technologies do not adequately utilize bacteria-derived nanovesicles for disease diagnosis or treatment.
Innovation Solution
The use of nanovesicles derived from bacteria belonging to the genus Sphingomonas for diagnosing and treating the mentioned diseases, involving the extraction of DNA from these vesicles, PCR analysis, and administration of vesicles as a pharmaceutical, food, or cosmetic composition to deliver drugs and regulate inflammatory responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bacteria-derived vesicles are used for disease diagnosis and treatment, then diagnostic accuracy and therapeutic effectiveness are improved, but measurement precision and reliability requirements increase
Solution Approach 1:
The patent replaces complex mechanical/direct observation methods with molecular biology techniques (PCR amplification of 16S rDNA) to detect and quantify bacterial vesicles. This substitution enables more precise and reliable detection of vesicle content without requiring direct visual observation or complex mechanical analysis, thereby resolving the contradiction between measurement precision and reliability requirements.
2Reliability
If Sphingomonas vesicles are administered for disease treatment, then therapeutic effects are improved, but control over vesicle distribution and absorption increases difficulty
Solution Approach 1:
The patent employs feedback mechanisms through quantitative PCR analysis to monitor vesicle distribution and absorption in real-time. By measuring the amount of Sphingomonas vesicles in different tissues and adjusting administration protocols accordingly, the system achieves controlled distribution while maintaining therapeutic effectiveness, resolving the contradiction between treatment reliability and distribution control difficulty.
3Adaptability or versatility
If comprehensive disease coverage is achieved, then adaptability is improved, but device complexity and analysis requirements increase
Solution Approach 1:
The patent develops a universal diagnostic and therapeutic platform based on Sphingomonas vesicles that can be applied across multiple disease types (hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, neurological disorders, and skin conditions). The same vesicle-based approach and PCR analysis method serve all these different diseases, achieving comprehensive coverage without proportionally increasing system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively diagnoses and treats the mentioned diseases by quantifying vesicle content in clinical samples and administering Sphingomonas-derived vesicles to reduce inflammatory mediators, with the vesicles being absorbed and distributed systemically, providing a potential drug delivery mechanism to the brain.
Implementation Method 1
vesicles derived from bacteria have a size of 100 nanometers or less and are absorbed into our bodies after relatively freely passing through epithelial cells via the mucosa
Implementation Method 2
the vesicles having passed through the epithelial cells are systematically absorbed via lymphatic vessels and thereby distributed in respective organs
Implementation Method 3
Bacteria-derived vesicles that are locally secreted from bacteria are absorbed via epithelial cells of the mucous membrane to thereby induce a local inflammatory response
Implementation Method 4
performing polymerase chain reaction (PCR) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA
Data Source
AI summary
The present invention relates to vesicles derived from bacteria of the genus Sphingomonas and a use thereof. These vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals. Administration of isolated vesicles suppressed secretion of inflammatory mediators by pathogenic vesicles such as E. coli-derived vesicles. Upon oral administration, the vesicles were distributed in the brain tissue. Vesicles derived from bacteria of the genus Sphingomonas are envisioned for use in methods of diagnosis, as well as compositions and methods for treating, hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis. These vesicles are also useful as drug carriers for drug delivery to the brain.